Ta strona została przetłumaczona automatycznie i dokładność tłumaczenia nie jest gwarantowana. Proszę odnieść się do angielska wersja za tekst źródłowy.

Effects of Hirudotherapy, Phytotherapy, and Forest Therapy in Adults With Reduced Work Capacity or Special Needs (CAM-HPMT)

13 lipca 2026 zaktualizowane przez: Laura Zaliene, Klaipėda University

Evaluation of the Biological Effects of Complementary and Alternative Health Care Services, Including Forest Therapy, Phytotherapy, and Hirudotherapy, in Individuals With Reduced Work Capacity and/or Special Needs

This interventional study will evaluate the effects of three complementary and alternative health care services-forest therapy, phytotherapy, and hirudotherapy-in individuals with a participation level below 55% and/or special needs. Participants will be assigned to one of three intervention groups or to a control group. The study will assess changes in blood pressure, body composition, handgrip strength, psychological well-being, perceived stress, and sleep quality before and after the intervention period. Safety, accessibility, feasibility, and acceptability of the services will also be evaluated. The findings will be used to develop standardized and evidence-informed recommendations for providing these services to people with reduced participation and/or special needs.

Przegląd badań

Szczegółowy opis

This randomized controlled interventional study will evaluate the biological, functional, and psychosocial effects of complementary and alternative health care services in individuals with a participation level below 55% and/or special needs. The study is designed to generate evidence for the development of standardized, accessible, and evidence-informed protocols for forest therapy, phytotherapy, and hirudotherapy.

A total of 100 participants will be enrolled and allocated to four groups of approximately 25 participants each: a phytotherapy group, a forest therapy group, a hirudotherapy group, and a control group receiving no study-related complementary and alternative health care intervention. Participants in the phytotherapy group will receive three phytotherapy sessions, participants in the forest therapy group will receive ten forest therapy sessions, and participants in the hirudotherapy group will receive six hirudotherapy sessions. The interventions will be delivered by appropriately qualified and licensed practitioners in accordance with Lithuanian legal and professional requirements.

Assessments will be conducted before and after the intervention period. Physiological and functional assessments will include blood pressure, body composition, and handgrip strength. Psychosocial outcomes will include psychological well-being, perceived stress, and sleep quality, assessed using standardized questionnaires, including the WHO-5 Well-Being Index, the 10-item Perceived Stress Scale, and the Pittsburgh Sleep Quality Index. Pre-intervention and post-intervention outcomes will be compared within and between the intervention and control groups.

The study will also evaluate the feasibility, accessibility, safety, and acceptability of providing these services to individuals with reduced participation and/or special needs. Reasonable accommodations may include accessible locations, adapted information formats, assistance with transportation or mobility, and support from accompanying persons when required.

Participant safety will be monitored throughout the study. Eligibility, contraindications, and potential risks will be assessed before the interventions. Any adverse events or unexpected reactions will be documented and evaluated. Particular attention will be given to contraindications and safety requirements associated with phytotherapy and hirudotherapy.

The results will be used to prepare standardized methodological materials and practical recommendations for complementary and alternative health care practitioners, health promotion programs, and social inclusion services.

Typ studiów

Interwencyjne

Zapisy (Szacowany)

100

Faza

  • Nie dotyczy

Kontakty i lokalizacje

Ta sekcja zawiera dane kontaktowe osób prowadzących badanie oraz informacje o tym, gdzie badanie jest przeprowadzane.

Lokalizacje studiów

    • Klaipėda County
      • Klaipėda, Klaipėda County, Litwa, LT-92294
        • Klaipeda University, Faculty of Health Sciences

Kryteria uczestnictwa

Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.

Kryteria kwalifikacji

Wiek uprawniający do nauki

  • Dziecko
  • Dorosły
  • Starszy dorosły

Akceptuje zdrowych ochotników

Nie

Opis

Inclusion Criteria:

Individuals with a participation level below 55% and/or officially recognized special needs.

Ability and willingness to participate in the study procedures and assigned intervention.

Provision of written informed consent by the participant or, where applicable, by a legally authorized representative.

Ability to complete the planned assessments independently or with reasonable assistance.

Medical condition sufficiently stable to participate in the assigned complementary and alternative health care intervention.

Willingness to attend baseline and post-intervention assessments and the scheduled intervention sessions.

Exclusion Criteria:

Acute illness, fever, active infection, or clinically unstable health condition at the time of enrollment.

Any medical condition that, in the investigator's or intervention provider's judgment, would make participation unsafe.

Known contraindication to the intervention to which the participant may be assigned.

Current participation in another interventional study that could affect the study outcomes.

Inability to provide informed consent and absence of a legally authorized representative.

Inability to comply with the study procedures or intervention schedule despite reasonable accommodations.

Planned major medical procedure or substantial change in treatment during the study period that could influence the study outcomes.

Additional intervention-specific exclusion criteria:

Phytotherapy: known allergy or hypersensitivity to the planned herbal products; clinically relevant interactions with current medications; pregnancy or breastfeeding, when relevant to the selected herbal product; severe hepatic or renal impairment where the planned preparation may be contraindicated.

Hirudotherapy: bleeding disorders; clinically significant anemia; current anticoagulant or antiplatelet therapy when considered unsafe by the treating clinician; immunodeficiency; active skin infection or lesion at the planned application site; known allergy to leech-related substances; other contraindications identified by the licensed hirudotherapy practitioner.

Forest therapy: acute condition limiting safe participation outdoors; uncontrolled cardiovascular or respiratory symptoms; severe mobility, cognitive, behavioral, or sensory limitations that cannot be safely accommodated; severe allergy or environmental sensitivity relevant to the planned setting.

-

Plan studiów

Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.

Jak projektuje się badanie?

Szczegóły projektu

  • Główny cel: Badania usług zdrowotnych
  • Przydział: Randomizowane
  • Model interwencyjny: Przydział równoległy
  • Maskowanie: Brak (otwarta etykieta)

Broń i interwencje

Grupa uczestników / Arm
Interwencja / Leczenie
Eksperymentalny: Phytotherapy Group
Participants assigned to this arm will receive three phytotherapy sessions delivered by a qualified complementary and alternative health care practitioner. The services will use legally permitted and appropriately sourced herbal products in accordance with Lithuanian professional and safety requirements. Physiological, functional, and psychosocial outcomes will be assessed before and after the intervention period.
Participants assigned to the phytotherapy arm will receive three individualized phytotherapy sessions delivered by a qualified complementary and alternative health care practitioner. The intervention may include assessment, selection, and use of legally permitted herbal preparations or herbal products appropriate to the participant's health status and special needs. Products will not be presented as investigational medicinal products. Contraindications, possible interactions, tolerability, and adverse reactions will be assessed and monitored throughout the intervention period.
Eksperymentalny: Forest Therapy Group
Participants assigned to this arm will receive ten structured forest therapy sessions delivered by a qualified forest therapy practitioner. Sessions will be adapted to participants' functional abilities and special needs and will be conducted in accessible natural environments. Physiological, functional, and psychosocial outcomes will be assessed before and after the intervention period.
Participants assigned to the forest therapy arm will receive ten structured forest therapy sessions delivered by a qualified forest therapy practitioner. Sessions will take place in accessible natural or forest environments and may include guided slow walking, sensory awareness, breathing, relaxation, mindful attention, and reflective activities. Session content and pace will be adapted to participants' functional abilities and special needs. Attendance, tolerability, and any adverse events will be documented.
Eksperymentalny: Hirudotherapy Group
Participants assigned to this arm will receive six hirudotherapy sessions delivered by a qualified and licensed hirudotherapy practitioner. Eligibility and contraindications will be assessed before treatment, and participant safety and adverse events will be monitored throughout the intervention period. Physiological, functional, and psychosocial outcomes will be assessed before and after the intervention period.
Participants assigned to the hirudotherapy arm will receive six hirudotherapy sessions delivered by a qualified and licensed practitioner. Before the intervention, eligibility and contraindications will be assessed. Medicinal leeches will be applied according to an individualized protocol, taking into account the participant's health condition and safety requirements. Participants will be monitored for bleeding, local skin reactions, infection, allergic reactions, and other adverse events during and after each session.
Brak interwencji: Control Group
Participants assigned to this arm will not receive a study-related complementary and alternative health care intervention during the study period. They will undergo the same baseline and post-intervention assessments as participants in the intervention groups.

Co mierzy badanie?

Podstawowe miary wyniku

Miara wyniku
Opis środka
Ramy czasowe
Change in Systolic Blood Pressure
Ramy czasowe: Baseline and after completion of the intervention period, approximately 3 months after baseline
Change in resting systolic blood pressure from baseline to the post-intervention assessment. Blood pressure will be measured in millimeters of mercury (mmHg) using a standardized procedure. A lower post-intervention value compared with baseline will indicate a reduction in systolic blood pressure.
Baseline and after completion of the intervention period, approximately 3 months after baseline
Change in Diastolic Blood Pressure
Ramy czasowe: Baseline and after completion of the intervention period, approximately 3 months after baseline
Change in resting diastolic blood pressure from baseline to the post-intervention assessment. Blood pressure will be measured in millimeters of mercury (mmHg) using a standardized procedure. A lower post-intervention value compared with baseline will indicate a reduction in diastolic blood pressure.
Baseline and after completion of the intervention period, approximately 3 months after baseline

Miary wyników drugorzędnych

Miara wyniku
Opis środka
Ramy czasowe
Change in Psychological Well-Being Assessed With the WHO-5 Well-Being Index
Ramy czasowe: Baseline and after completion of the intervention period, approximately 3 months after baseline
Change in psychological well-being from baseline to the post-intervention assessment, measured using the 5-item World Health Organization Well-Being Index (WHO-5). The raw score ranges from 0 to 25, with higher scores indicating better psychological well-being. The raw score may also be multiplied by 4 to obtain a percentage score ranging from 0 to 100.
Baseline and after completion of the intervention period, approximately 3 months after baseline
Change in Perceived Stress Assessed With the PSS-10
Ramy czasowe: Baseline and after completion of the intervention period, approximately 3 months after baseline
Change in perceived stress from baseline to the post-intervention assessment, measured using the 10-item Perceived Stress Scale (PSS-10). The total score ranges from 0 to 40, with higher scores indicating greater perceived stress.
Baseline and after completion of the intervention period, approximately 3 months after baseline
Change in Sleep Quality Assessed With the Pittsburgh Sleep Quality Index
Ramy czasowe: Baseline and after completion of the intervention period, approximately 3 months after baseline
Change in sleep quality from baseline to the post-intervention assessment, measured using the Pittsburgh Sleep Quality Index (PSQI). The global score ranges from 0 to 21, with higher scores indicating poorer sleep quality.
Baseline and after completion of the intervention period, approximately 3 months after baseline
Change in Handgrip Strength
Ramy czasowe: Baseline and after completion of the intervention period, approximately 3 months after baseline
Change in maximal handgrip strength from baseline to the post-intervention assessment. Handgrip strength will be measured in kilograms using a hand dynamometer under standardized testing conditions. Higher values indicate greater grip strength.
Baseline and after completion of the intervention period, approximately 3 months after baseline
Change in Body Fat Percentage
Ramy czasowe: Baseline and after completion of the intervention period, approximately 3 months after baseline
Change in body fat percentage from baseline to the post-intervention assessment, measured using a standardized body composition analyzer. Lower or higher values will be interpreted according to the participant's individual health status.
Baseline and after completion of the intervention period, approximately 3 months after baseline
Change in Body Weight
Ramy czasowe: Baseline and after completion of the intervention period, approximately 3 months after baseline
Change in body weight from baseline to the post-intervention assessment. Body weight will be measured in kilograms using a standardized body composition analyzer, with participants assessed under comparable measurement conditions.
Baseline and after completion of the intervention period, approximately 3 months after baseline
Change in Body Mass Index
Ramy czasowe: Baseline and after completion of the intervention period, approximately 3 months after baseline
Change in body mass index from baseline to the post-intervention assessment. Body mass index will be calculated as body weight in kilograms divided by height in meters squared and reported in kg/m².
Baseline and after completion of the intervention period, approximately 3 months after baseline
Change in Skeletal Muscle Mass
Ramy czasowe: Baseline and after completion of the intervention period, approximately 3 months after baseline
Change in skeletal muscle mass from baseline to the post-intervention assessment. Skeletal muscle mass will be estimated in kilograms using a standardized bioelectrical impedance body composition analyzer under comparable measurement conditions.
Baseline and after completion of the intervention period, approximately 3 months after baseline
Change in Visceral Fat Level
Ramy czasowe: Baseline and after completion of the intervention period, approximately 3 months after baseline
Change in visceral fat level from baseline to the post-intervention assessment. Visceral fat will be estimated using a standardized bioelectrical impedance body composition analyzer and reported according to the device-specific visceral fat rating scale. Lower scores indicate a lower estimated level of visceral fat.
Baseline and after completion of the intervention period, approximately 3 months after baseline

Współpracownicy i badacze

Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.

Śledczy

  • Główny śledczy: Laura Zaliene, PhD, Klaipėda University

Publikacje i pomocne linki

Osoba odpowiedzialna za wprowadzenie informacji o badaniu dobrowolnie udostępnia te publikacje. Mogą one dotyczyć wszystkiego, co jest związane z badaniem.

Daty zapisu na studia

Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.

Główne daty studiów

Rozpoczęcie studiów (Rzeczywisty)

15 kwietnia 2026

Zakończenie podstawowe (Szacowany)

20 grudnia 2026

Ukończenie studiów (Szacowany)

20 grudnia 2026

Daty rejestracji na studia

Pierwszy przesłany

13 lipca 2026

Pierwszy przesłany, który spełnia kryteria kontroli jakości

13 lipca 2026

Pierwszy wysłany (Rzeczywisty)

16 lipca 2026

Aktualizacje rekordów badań

Ostatnia wysłana aktualizacja (Rzeczywisty)

16 lipca 2026

Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości

13 lipca 2026

Ostatnia weryfikacja

1 lipca 2026

Więcej informacji

Terminy związane z tym badaniem

Plan dla danych uczestnika indywidualnego (IPD)

Planujesz udostępniać dane poszczególnych uczestników (IPD)?

NIEZDECYDOWANY

Informacje o lekach i urządzeniach, dokumenty badawcze

Bada produkt leczniczy regulowany przez amerykańską FDA

Nie

Bada produkt urządzenia regulowany przez amerykańską FDA

Nie

Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .

Subskrybuj